Acute Kidney Injury in Critical COVID-19: Outcomes and Risks

Completed

• Conditions: COVID -19; Acute Kidney Injury; Intensive Care Unit (ICU) Admission; Mortality

• Registration Number: NCT07089693
• Lead Sponsor: Ankara University

Brief Summary

This retrospective observational study aims to determine the incidence of acute kidney injury (AKI) associated with COVID-19, risk factors, and effects on mortality for intensive care unit patients. Data from 238 COVID-19 patients monitored in the Anesthesiology and Reanimation Intensive Care Unit of Ankara University Ibni Sina Hospital between January 1, 2021 and January 1, 2022 were retrospectively reviewed. Patients were divided into two groups according to the level of renal damage (with and without AKI). Those with AKI were staged per the KDIGO criteria (Stage 1-2-3). Demographic data, comorbidities, Charlson comorbidity indexes, Acute Physiology and Chronic Health Evaluation scores, laboratory results, and mortality data were examined. The data obtained were compared between the groups.

The findings may help improve clinical awareness and guide management strategies in intensive care unit patients with COVID-19 at risk of AKI

Detailed Description

This retrospective, single-center observational study was conducted at Ankara University Hospital. Data from 238 COVID-19 patients monitored in the Anesthesiology and Reanimation Intensive Care Unit of Ankara University Ibni Sina Hospital between January 1, 2021 and January 1, 2022 were retrospectively reviewed. The objective of the study was to investigate the frequency, risk factors, and impact on mortality of acute kidney injury (AKI) in adult patients hospitalized with confirmed COVID-19 infection.

Patients with a confirmed diagnosis of COVID-19 and available renal function data were included in the analysis. AKI was defined and staged according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria. Demographic characteristics, comorbidities, laboratory values, and clinical parameters were evaluated to identify potential risk factors for AKI development. The relationship between the presence and severity of AKI and in-hospital mortality was assessed.

The study aims to provide insight into the burden of COVID-19-associated AKI and to support improved clinical decision-making for identifying and managing high-risk patients in hospital settings.

Study Timeline

• Study Start: 2022-07-01
• Primary Completion: 2022-07-30
• Study Completion: 2022-08-15
• Status Verified: 2025-07
• Study First Submitted: 2025-07-21
• Study First Submitted QC: 2025-07-22
• Last Update Submitted: 2025-07-22
• Study First Posted: 2025-07-28
• Last Update Posted: 2025-07-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 238

Inclusion Criteria

• Age 18 years or older
• Hospitalized patients with COVID-19 confirmed by PCR test
• Required follow-up in the intensive care unit between January 1, 2021 and January 1, 2022

Exclusion Criteria

• Patients with end-stage renal disease (ESRD)
• History of renal transplantation
• Intensive care unit stay shorter than 48 hours

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Intensive care unit mortality	From ICU admission until in-hospital death or ICU discharge, whichever occurs first, assessed up to 90 days.	To evaluate whether the development of AKI is associated with mortality in COVID-19 patients monitored in the intensive care unit.

Secondary Outcome Measures

Name	Time	Method
Association between patient characteristics and AKI development	From ICU admission until AKI diagnosis or ICU discharge, assessed up to 100 days.	To identify clinical and laboratory predictors associated with AKI development in COVID-19 patients requiring intensive care, using retrospective data analysis.
Length of intensive care unit stay	From ICU admission until ICU discharge, assessed up to 12 months.	To assess whether the development of AKI in COVID-19 patients is associated with the length of stay in the intensive care unit.
Incidence of acute kidney injury	From ICU admission until AKI diagnosis or ICU discharge, whichever occurs first, assessed during hospitalization (up to 100 days).	To determine the incidence of AKI among COVID-19 patients, defined by the KDIGO criteria.

Trial Locations

Locations (1)

Ankara University; 🇹🇷 Ankara, Turkey